Skip to search formSkip to main contentSkip to account menu

Anticancer Drugs - Consent type

Known as: Anticancer Drugs 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Cytotoxic Effects of Phosphonate-Functionalized Mesoporous Silica Nanoparticles.
In this work, we synthesized pristine mesoporous silica nanoparticles (MSN) and functionalized these with phosphonate groups (MSN… 
Review
2016
Review
2016
Current situation and future usage of anticancer drug databases
Cancer is a deadly disease with increasing incidence and mortality rates and affects the life quality of millions of people per… 
2016
2016
The leaching behavior of cyclophosphamide and ifosfamide from soil in the presence of co-contaminant--Mixture sorption approach.
Review
2010
Review
2010
An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project
PurposeCancer patients are at high risk of manifesting interactions from use of anticancer drugs (ACDs) and complementary and… 
2010
2010
Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians
Background: Existing research has suggested that there can be potential drug-drug interaction (DDI) between antiepileptic drugs… 
2008
2008
Distinguishing compounds with anticancer activity by ANN using inductive QSAR descriptors
This article describes a method developed for predicting anticancer/non-anticancer drugs using artificial neural network (ANN… 
Review
2006
Review
2006
Fluorescence studies of anti-cancer drugs--analytical and biomedical applications.
The fluorescence properties of anticancer drugs (ACDs), including steady-state native fluorescence, time-resolved fluorescence… 
2005
2005
Prescription Errors with Cytotoxic Drugs and the Inadequacy of Existing Classifications
Objective: To quantify the amount of potential prescription errors for anticancer drugs in order to improve the quality of care… 
1999
1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
The failure of convenional chemotherapy in relapsed or refractory and other poor risk AML patients has been linked to expression… 
Review
1997
Review
1997
[SDZ PSC 833: a novel modulator of MDR].
SDZ PSC 833 is a novel compound able to reverse the resistance to chemotherapy of cancer cells with the multidrug resistance (MDR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)